Ixekizumab treatment is associated with a high level of skin clearance in patients with psoriasis., After 3 years of ixekizumab treatment, a majority of patients sustained a PASI 90 response, with no new safety signals.. Ixekizumab is a reasonable long-term treatment option for patients with moderate-to-severe plaque psoriasis.
Πέμπτη 24 Μαΐου 2018
Maintenance of Skin Clearance With Ixekizumab Treatment of Psoriasis: Three-Year Results From the UNCOVER-3 Study
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Small molecule inhibitor of the Wnt pathway (SM04755) as a potential topical treatment for psoriasisBackground: Psoriasis (PSO) is an autoimmune disease causing patches of thick, inflamed, scaly skin due to excessive proliferation of skin c...
-
Clinical and animal studies show that ethanol exposure and inflammation during pregnancy cause similar behavioral disturbances in the offspr...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.